Economic information and modeling report
Modeling overview
7 evidence topics · 6 sources
Summary: published economic evaluations
No cost-effectiveness analysis or budget impact model of rinzimetostat was identified. Published U.S. models address comparators and the combination partner. A partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel from a U.S. health care perspective (60-month horizon, 3% annual discount for costs, January 2025 dollars) estimated 0.86 versus 0.76 QALYs, mean total costs of $165,958 versus $129,700, and an ICER of $358,990 per QALY gained; results were most sensitive to the overall survival hazard ratio and the per-cycle costs of both treatments. Authors employed by Sanofi, the manufacturer of cabazitaxel, state that the model used the price of 177Lu-DOTATATE as a proxy for a per-cycle cost of $32,062. A U.S. payer cost model of third-line cabazitaxel versus a second androgen receptor-targeted agent over 18 months estimated $323,095 (17%) in avoided total costs, driven by the management of symptomatic skeletal events and end-of-life care; the CARD trial used cabazitaxel 25 mg/m2, while 20 mg/m2 is used in U.S. practice. A U.S. payer model of genomic test-directed olaparib after a new hormonal agent (2019 dollars) estimated an ICER of $116,903 per QALY in one scenario and cost savings in the other. For darolutamide, a U.S. payer budget impact model in nmCRPC for a 1-million-member plan over 5 years estimated a budget increase of $158,640 ($0.0132 PMPM) in year 1 and savings of $149,240 ($0.0124 PMPM) by year 5, and a U.S. hospitalization budget impact analysis of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer reported a cumulative budget impact of -$9.71 per treated member per month over 5 years.
Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model
“In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis was conducted over a lifetime horizon of 60 mo with a 1-mo cycle length on the basis that over 99% of patients in our model transitioned to a terminal state within this period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An annual discount of 3% for costs was applied in the analysis in accordance with recommendations from the Second U.S. Panel on Cost-Effectiveness in Health and Medicine (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were adjusted to January 2025 U.S. dollars using the medical care component of the Consumer Price Index (23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base case analysis, 177Lu-PSMA-617 was associated with an average of 0.86 QALYs, compared with 0.76 QALYs for cabazitaxel. The mean total costs were $165,958 for 177Lu-PSMA-617 and $129,700 for cabazitaxel, resulting in an incremental cost of $36,258 and an incremental QALY gain of 0.10. This corresponded to an ICER of $358,990/QALY gained, exceeding the highest U.S. WTP threshold of $200,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At WTP thresholds of $50,000/QALY, $100,000/QALY, and $200,000/QALY, the corresponding maximum cost per cycle that would make 177Lu-PSMA-617 cost-effective was $23,499, $24,885, and $27,656, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acquisition cost input of the lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model
“The authors note that direct U.S. cost data for 177Lu-PSMA-617 were not available and therefore used the price of 177Lu-DOTATATE as a proxy, citing a pan-Canadian Oncology Drug Review (pCODR) report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case per-cycle cost for 177Lu-PSMA-617 was $32,062, with a sensitivity range of $25,649–$38,474, reflecting a 20% variation around the base case (i.e., 80%–120%), consistent with the underlying Advanced Accelerator Applications model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the directional conclusion is unlikely to change, the magnitude of difference is likely greater than reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kyle Flannery, Paul Cavanaugh, and Kevin Steele are employees of Sanofi, the manufacturer of Jevtana (cabazitaxel) injection, and may hold shares or options in the company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model
“We aimed to estimate healthcare costs avoided with the use of cabazitaxel as a third-line (3 L) treatment versus a second ARTA from a US payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the short life expectancy for the target population (median OS of 11.0–13.6 months) [19], a time horizon of 18 months was used for the reference case analysis, and scenario analyses were conducted for time horizons of 6, 12, and 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The economic analysis included the costs associated with the management of SSEs, AEs, and end-of-life care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cabazitaxel, as compared with a second ARTA, was associated with 58 fewer hospitalization days and 2 fewer ICU days and was estimated to avoid $323,095 (€274,630, 17%) in total costs, driven by SSEs management and end-of-life care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CARD trial evaluated the 25 mg/m2 dose of cabazitaxel, while 20 mg/m2 is routinely used in clinical practice in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genomic test-directed olaparib after a new hormonal agent: U.S. payer cost-effectiveness model
“We aimed to evaluate the cost-effectiveness of genomic test-directed olaparib on MCRPC from the US payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A mathematical model combining a decision tree and partitioned survival model was established to measure the clinical and economic outcomes of olaparib and standard care for men with MCRPC who had disease progression while receiving a new hormonal agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct medical costs were considered from a United States payer perspective, which was reported in 2019 United States dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darolutamide in nonmetastatic castration-resistant prostate cancer: U.S. payer budget impact model
“A budget impact model was developed to evaluate darolutamide for nmCRPC for a hypothetical 1-million-member plan over a 5-year period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs (drug acquisition, drug administration, and treatment-related adverse events [AEs]) were estimated for 2 scenarios: with and without darolutamide treatment for nmCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Market share estimates were derived from interviews with physicians treating men with nmCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For a plan with 1 million lives, there were approximately 90 incident cases of nmCRPC (46 high risk) each year, with 332 (109 high risk) treatment-eligible cases by year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the utilization of other agents, introducing darolutamide along with other targeted therapies was predicted to increase the total budget by $158,640 ($0.0132 per member per month [PMPM]) in year 1, which decreased over time to a cost savings of $149,240 ($0.0124 PMPM) by year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darolutamide with docetaxel in metastatic hormone-sensitive prostate cancer: U.S. hospitalization budget impact analysis
“Based on these estimates, a budget impact analysis evaluated the hospitalization costs (including ICU admissions) and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote